Levi & Korsinsky Announce Class Action Lawsuit Against Actinium Pharmaceuticals and Upcoming Deadline for Investors
On May 13, 2025, the law firm Levi & Korsinsky LLP informed shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) about a class action lawsuit related to potential securities fraud. The lawsuit specifically targets investors affected by events occurring between October 31, 2022, and August 2, 2024. In essence, the lawsuit claims that the company misrepresented crucial data from its Phase 3 Sierra trial, which is pivotal for the approval of its targeted radiotherapy, Iomab-B.
According to the allegations, the data from the Sierra trial was unlikely to meet the standards set forth by the FDA, raising significant concerns about the approval of the drug's Biologics License Application (BLA). Plaintiffs in this class action argue that the defendants failed to disclose important information regarding the clinical trial outcomes and their implications for FDA review.
Key points highlighted in the lawsuit include the assertion that the additional analyses conducted to showcase a potential trend towards improved overall survival rates were probably insufficient to satisfy the FDA’s stringent guidelines. Consequently, this misrepresentation may have led to misleading positive statements about the company’s prospects and operations.
Investors who suffered financial losses during the specified timeframe are encouraged to act swiftly, as the deadline to request lead plaintiff status is May 27, 2025. While appointing a lead plaintiff is not a requirement for participation in the case, acting quickly is crucial for those seeking compensation.
Notably, the law firm, Levi & Korsinsky, has a significant track record in securities litigation. With two decades of experience, they have successfully secured substantial financial recoveries for shareholders in class action suits and have been recognized among the top securities litigation firms in the United States for seven consecutive years.
The law firm offers these services without any upfront costs; members of the class may be eligible for compensation without incurring any financial burden. Individuals interested in joining the class action are encouraged to reach out directly to Levi & Korsinsky’s team, particularly Joseph E. Levi, Esq., via email or phone.
For impacted investors, this lawsuit represents a critical opportunity to seek redress for losses incurred due to alleged misrepresentations by Actinium Pharmaceuticals. More information can be found by following the link provided by the law firm, which outlines the necessary steps for participation in this class action lawsuit. As the deadline approaches, aggrieved investors should ensure they understand their rights and options for potential recovery as they navigate this complex legal landscape.
According to the allegations, the data from the Sierra trial was unlikely to meet the standards set forth by the FDA, raising significant concerns about the approval of the drug's Biologics License Application (BLA). Plaintiffs in this class action argue that the defendants failed to disclose important information regarding the clinical trial outcomes and their implications for FDA review.
Key points highlighted in the lawsuit include the assertion that the additional analyses conducted to showcase a potential trend towards improved overall survival rates were probably insufficient to satisfy the FDA’s stringent guidelines. Consequently, this misrepresentation may have led to misleading positive statements about the company’s prospects and operations.
Investors who suffered financial losses during the specified timeframe are encouraged to act swiftly, as the deadline to request lead plaintiff status is May 27, 2025. While appointing a lead plaintiff is not a requirement for participation in the case, acting quickly is crucial for those seeking compensation.
Notably, the law firm, Levi & Korsinsky, has a significant track record in securities litigation. With two decades of experience, they have successfully secured substantial financial recoveries for shareholders in class action suits and have been recognized among the top securities litigation firms in the United States for seven consecutive years.
The law firm offers these services without any upfront costs; members of the class may be eligible for compensation without incurring any financial burden. Individuals interested in joining the class action are encouraged to reach out directly to Levi & Korsinsky’s team, particularly Joseph E. Levi, Esq., via email or phone.
For impacted investors, this lawsuit represents a critical opportunity to seek redress for losses incurred due to alleged misrepresentations by Actinium Pharmaceuticals. More information can be found by following the link provided by the law firm, which outlines the necessary steps for participation in this class action lawsuit. As the deadline approaches, aggrieved investors should ensure they understand their rights and options for potential recovery as they navigate this complex legal landscape.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.